Drugs.com: More naloxone orders filled when pharmacists can dispense

UC research on naloxone dispensing makes headlines across the country

Pharmacy researchers at the University of Cincinnati unveiled an impactful research study on Jan. 31, 2020 that shows an association between a 2015 Ohio law and a surge in the dispensing of naloxone in Ohio pharmacies. Naloxone is the anti-overdose drug and pharmacists here can now legally dispense it in the state, without a prescription.

While the study focused solely on the increase in distribution of this lifesaving medication,  the implications are that death rates by overdose drop up to 14% in states where access is increased. As the opioid crisis continues to plague the U.S. and other countries, reporters from national, regional and local outlets took great interest in the study. The college dean, Neil MacKinnon, and lead faculty researcher, Pamela Heaton, participated in both televsion and print media interviews within days of the study's release.

A sample of the widespread interest includes: 

 

Featured image: generic pharmacy purchases/unsplash.com/Tbel Abuseridze

Related Stories

1

Recent advances may speed time to endometriosis diagnosis

March 16, 2026

The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.

3

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.